Point of View: COVID-19 as a catalyst for reimagining cervical cancer prevention
- Beth Israel Deaconess Medical Center, Harvard Medical School, United States
- Brigham and Women’s Hospital, Harvard Medical School, United States
- University of Malaya, Malaysia
- University of California, Los Angeles, United States
- H Lee Moffitt Cancer Center and Research Institute, United States
- National Cancer Institute, United States
- ISGlobal, Spain
- Charité - Universitätsmedizin Berlin, Germany
- Freie Universität Berlin, Germany
- Humboldt Universität zu Berlin, Germany
- McGill University Health Centre, Canada
- Pima County, United States
- University of Hong Kong, China
- All India Institute of Medical Sciences, India
- University of Cambridge, United Kingdom
- Australian Centre for the Prevention of Cervical Cancer, Australia
- University of California, San Francisco, United States
- Melbourne Medical School, Royal Women’s Hospital, Australia
Figures
Figure 1
Map showing ever-in-lifetime cervical cancer screening coverage in women aged 30–49 years in 2019 by country.
This map demonstrates that only 75 of the 202 countries surveyed in this study had achieved screening coverage of 70% or higher. Most countries in Africa and South Asia have lifetime screening coverage less than 20%. From Bruni et al., 2022. Lancet Global Health 10:e1115–1127. (CC BY 4.0).
Figure 2
Map showing the age-standardised incidence of cervical cancer by country, estimated for 2018.
The countries with the highest incidence of cervical cancer (in parts of sub-Saharan Africa, south Asia and South America) largely correspond to the countries with low screening coverage. From Arbyn et al., 2020. Lancet Global Health 8:e191–e203. (CC BY 4.0).
Figure 3
Map showing the self-sampling approach in countries that officially recommend HPV-based screening.
As of October 2020, few countries had introduced HPV primary screening, and most were concentrated in high-income countries. Only 17 countries had introduced HPV self-sampling into their national programs or guidelines and of those, half reserved the use of self-sampling for under-screened populations only. From Serrano et al., 2022. Preventive Medicine 154:106900. (CC BY 4.0).
Additional files
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Point of View: COVID-19 as a catalyst for reimagining cervical cancer prevention
eLife 12:e86266.
https://doi.org/10.7554/eLife.86266
